Our platforms cover antibodies, small molecules, cell therapy, natural products, peptides, and RNA, all built on the same protein / chemistry foundation models, benchmarked against the same wet-lab reality.
Built on AINN-P1, our 167M-parameter protein foundation model. End-to-end: de novo antibody design, affinity maturation, bispecific/multispecific engineering, format conversion. Picomolar leads on 15 of 40 validated targets.
Each engine shares core infrastructure with SentinusAI: proprietary training data, continuous wet-lab calibration, and a published-benchmark discipline.
De novo small-molecule generation, PROTAC design, scaffold hopping, CRBN neosubstrate selectivity panels. Virtual screening of 1010 compounds overnight. SynMagic™ retrosynthetic planning for any lead.
CAR construct optimization, activation and persistence modeling for CAR-T, allogeneic cell therapies, and gene-edited cellular products. 10× faster cell-line development vs standard pipelines.
Next-generation peptide therapeutics with enhanced stability, selectivity, and bioavailability. Cyclic, stapled, GLP-1 analogs, rapid sequence optimization across diverse therapeutic areas.
Computational expansion and optimization of natural-product chemical space. Unlocks the therapeutic potential of plant and microbial compound libraries while maintaining the properties that make them bioactive.
Design of optimized RNA therapeutics, mRNA, siRNA, ASOs. Secondary structure prediction, stability modeling, efficacy ranking across sequence space.
Bring us a target. We assemble the right platforms, run the campaign, and deliver wet-lab-validated candidates with freedom-to-operate analysis, typically in weeks, not quarters.
Pick any of the six, we'll scope a pilot campaign and share representative wet-lab data from similar targets within a week.
Scope a pilot →